Navigation Links
FDA Approves Injectable Gel to Treat Fecal Incontinence

SILVER SPRING, Md., May 27, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a sterile, injectable gel to treat fecal incontinence in patients for whom other therapies such as diet change, fiber therapy or anti-motility medications failed.


Fecal incontinence is the involuntary loss of bowel control. It can have different causes including nerve damage, weakened anal sphincter associated with aging, or rectum muscle damage. According to the National Institutes of Health, there are more than 5.5 million Americans with fecal incontinence.

The Solesta gel is injected into a layer of tissue beneath the anus lining and may help build tissue in that area. By growing the surrounding tissue, the opening of the anus narrows and the patient may be able to better control those muscles.

"Fecal incontinence is difficult to treat," said Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health. "This approval provides a minimally invasive treatment option for patients with fecal incontinence that does not respond to conservative therapies."

The FDA based its approval on results from a clinical study of 206 patients. In the primary study, most patients received two treatments, consisting of four injections each, for a total of eight injections. After six months, more than half of the patients injected with Solesta experienced a 50 percent reduction in the number of fecal incontinence episodes. However, one-third of patients who received no Solesta in the study also experienced a similar reduction. Overall, a greater proportion of patients treated with Solesta experienced improvements, indicating the gel provides benefit.  

Solesta is approved for use in patients ages 18 and up. It should not be used in patients who have active inflammatory bowel disease, immunodeficiency disorders, previous radiation treatment to the pelvic area, significant rectal prolapse, active infections, bleeding, tumors or malformations in the anorectal area, rectal distended veins, an existing implant in the anorectal region, or allergy to hyaluronic acid based products.

The most common side effects associated with Solesta include injection area pain and bleeding. Infection and inflammation of anal tissue are more serious risks, but are less common.  

Solesta is manufactured by Oceana Therapeutics Inc. of Edison, N.J.

For more information:

Gastroenterology-Urology Devices Panel Advisory Committee Meeting Transcript from Dec. 2nd and Dec. 3rd, 2010. ( (

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Amanda Sena, 301-796-0393,
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA approves Incivek for hepatitis C
2. FDA Approves Sutent for Rare Type of Pancreatic Cancer
3. FDA Approves New HIV Treatment
4. FDA Approves Victrelis for Hepatitis C
5. FDA Approves New Treatment for Rare Type of Pancreatic Cancer
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
8. FDA Approves New Treatment for Type 2 Diabetes
9. FDA Approves Zytiga for Late-Stage Prostate Cancer
10. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
11. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
Post Your Comments:
(Date:12/1/2015)... 1, 2015 A federal court has denied the ... a lawsuit filed by the Pharmaceutical Care Management Association (PCMA) ... a new law that forces employers and consumers to pay ... Arkansas must now defend a law that raises ... and CEO Mark Merritt . --> ...
(Date:12/1/2015)... 2015  Athletic apparel company Tommie Copper ... pay $1.35 million to settle Federal Trade Commission ... compression clothing would relieve severe and chronic pain ... Tommie Copper,s proposed settlement ... its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... , Dec. 1, 2015 Assurex ... its GeneSight® Psychotropic test giving healthcare providers an expanded ... decisions for patients suffering from depression, anxiety, bipolar ... behavioral health conditions. i . ... --> With the addition of two new ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won a tender ... be from the China Disabled Persons’ Federation, a central government association, for nearly 2,000 ... and adults suffering from severe and profound hearing loss . The company holds ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Trust on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. ... the patient care experience, and propose exciting enhancements to the medical landscape. , ...
Breaking Medicine News(10 mins):